Loading...
Loading...
MNOV| Name | Value |
|---|---|
| Revenues | 134.6K |
| Cost of Revenue | 116.3K |
| Gross Profit | 18.2K |
| Operating Expense | 3,625.3K |
| Operating I/L | -3,607.1K |
| Other Income/Expense | 325.9K |
| Interest Income | 325.0K |
| Pretax | -3,281.2K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -3,281.2K |
MediciNova, Inc. is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for serious diseases with unmet medical needs. The company's primary focus is on the development of MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of various neurological disorders, including multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. Additionally, the company's product pipeline includes MN-221 (bedoradrine) for acute exacerbations of asthma, MN-001 (tipelukast) for fibrotic diseases, and MN-029 (denibulin) for solid tumor cancers.
